Clinical Trials

  • Principal Investigator:

    Andrew Jeffrey Einstein, MD
    Phase 3 open-label, multicenter Study of Flurpiridaz Injection for PET Imaging for assessment of Myocardial perfusion in patients referred for Invasive Coronary Angiography because of suspected Coronary Artery Disease
  • Principal Investigator:

    Hirad Yarmohammadi, MD
    We are doing this study to gather information on participants returning at time of Cardiovascular Implantable Electronic Device (CIED) change-out or revision who underwent a device implantation with either a CanGaroo envelope, Tyrx envelope, or no envelope. A CIED is a device implantable inside the body, able to conduct pacing of the heart and therefore capable of correcting most life-threatening abnormal heart rhythms. People who have had surgery to implant a medical device that helps their heart, may have had their surgery done in slightly different ways. In this study, the investigators...
  • Principal Investigator:

    Angelo Bartolo Biviano, MD
    A randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HSY244 in participants with AF. Participants will be randomized and assigned to one of the following 2 treatment arms in a ratio of 1:1. Arm 1: HSY244 intravenous infusion; Arm 2: Placebo intravenous infusion. The study consists of a screening period of up to 3 days and a treatment period of 4 days. After confirming eligibility on Day 1 and pre-dose assessments are completed, study administration will occur and participants will be monitored for...
  • Principal Investigator:

    Frederick Arthur Ehlert, MD
    The purpose of this registry is to collect information over time about how Medtronic products are working and/or the outcome of the treatment. The registry will be used to support post-market surveillance/monitoring activities and post-approval studies (e.g., to collect safety and performance information). In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines and patient services/solutions. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies...
  • Principal Investigator:

    Sahil A. Parikh, MD
    This is a prospective, multicentre observational study to evaluate the BioMimics 3D Vascular Stent System in the treatment of peripheral arterial disease. The purpose of the Study is to collect detailed information on the BioMimics 3D stent performance when used according to standard medical care. A Minimum of 500 patients will be enrolled in a two-year recruitment period at up to 40 sites. Patients will be evaluated at 30 days then 12, 24, and 36 months.
  • Principal Investigator:

    Susheel Kumar Kodali, MD
    This is a randomized controlled trial (RCT) that will compare the clinical outcome of MitraClip device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team. In this trial, each subject will be followed until their 10-year visit. Clinical Investigation visits will occur at Screening (for determination of eligibility), Baseline (after confirmation of eligibility), Index Procedure, Discharge, 30 days, 6 months, 1...
  • Principal Investigator:

    Justin Alan Fried, MD
    The purpose of this research is to evaluate the safety and performance of an experimental system called the Aortix System. The system is being designed for use in patients hospitalized for a worsening of their heart failure symptoms and who also show signs of strain on their kidneys. The Aortix System includes a pump, which we hope may help the heart and also help the kidneys to perform better. The system is being designed for use in patients hospitalized for a worsening of their heart failure symptoms and who also show signs of strain on their kidneys. Heart failure can make it difficult for...
  • Principal Investigator:

    Robert J. Sommer, MD
    This is a prospective, single arm, three stage, multi-site, clinical investigation evaluating the safety and efficacy of the Carag Bioresorbable Septal Occluder (CBSO) to treat patients with clinically significant hole in the atrial septal defect compared to other commercially approved devices. The study is being done to determine the safety and efficacy of a new device, called the Carag Bioresorbable SeptalOccluder (CBSO) device when used to treat Atrial Septal Defect (ASD). ASD is a condition that occurs at birth where there is a hole in the two upper chambers of the heart.
  • Principal Investigator:

    Marwah Abdalla, MD
    The Center for Behavioral Cardiovascular Health (CBCH) is conducting a research study to examine the impact that sleep hours have on blood pressure (BP) levels during sleep. Two-part screening to determine eligibility for this study involves a) answering questionnaires and b) documenting daily average sleep duration (how long you sleep) over the course of a 2-week period. Participation in the research study involves 1-4 study visits, wearing a Fitbit activity monitoring device for an additional 8-weeks, wearing a blood pressure measurement device and a heart monitoring patch device for 2...
  • Principal Investigator:

    Daichi Shimbo, MD
    The purpose of this clinical trial is to study the relationship of stress, salt excretion, and nighttime blood pressure. Blood pressure normally has a diurnal pattern: it is highest during the day and dips during the night. The effects of psychological stress can interfere with this normal pattern and cause elevated nighttime blood pressure or reduced blood pressure dipping. It is predicted that, in some individuals, psychological stress can interfere with the diurnal pattern of sodium excretion which, like blood pressure, is highest during the day and lowest at night. The purpose of this...

Pages